Sildenafil citrate linked to increased chorodial thickness

Article

phosphodiesterase-5 inhibitor, sildenafil citrate, increases chorodial thickness ? an associated risk factor for central serous chorioretinopathy

A study published in Retina shows the phosphodiesterase-5 inhibitor, sildenafil citrate, increases chorodial thickness – an associated risk factor for central serous chorioretinopathy.

Dr Susham K. Vance et al., LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, USA, conducted a prospective, interventional study involving the administration of 100 mg of sildenafil citrate to 8 subjects with no previous ocular history. Enhanced depth imaging spectral-domain optical coherence tomography was used to measure choroidal thickness in both eyes at 1-hour and 3-hour intervals after ingestion.

The findings demonstrated that the mean chorodial thickness had increased by 12.3% from 334 μm to 375 μm after 1-hour. The mean choroidal thickness was 11.6% thicker than baseline at the 3-hour interval. No significant changes were noted in choroidal thickness between the 1-hour and 3-hour intervals.

The results were related to previous studies of phosphodiesterase-5 inhibitors and central serous chorioretinopathy. Sildenafil citrate increases choroidal thickness both 1-hour and 3-hours after administration.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.